Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 5 studies | 20% ± 5% | |
epithelial cell | 4 studies | 33% ± 5% | |
microglial cell | 4 studies | 26% ± 5% | |
macrophage | 4 studies | 24% ± 8% | |
hepatocyte | 3 studies | 29% ± 7% |
Insufficient scRNA-seq data for expression of SPTLC3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 99% | 1554.47 | 88 / 89 | 98% | 22.23 | 887 / 901 |
thymus | 100% | 2442.40 | 653 / 653 | 97% | 18.22 | 585 / 605 |
ovary | 99% | 778.84 | 178 / 180 | 92% | 6.28 | 397 / 430 |
liver | 98% | 1205.50 | 221 / 226 | 86% | 6.92 | 349 / 406 |
breast | 97% | 602.85 | 443 / 459 | 85% | 7.12 | 949 / 1118 |
prostate | 96% | 739.50 | 236 / 245 | 76% | 3.60 | 380 / 502 |
pancreas | 85% | 345.06 | 278 / 328 | 85% | 4.94 | 152 / 178 |
uterus | 93% | 435.13 | 158 / 170 | 68% | 4.64 | 314 / 459 |
lung | 96% | 747.20 | 553 / 578 | 64% | 4.67 | 742 / 1155 |
bladder | 81% | 605.67 | 17 / 21 | 71% | 5.92 | 357 / 504 |
esophagus | 88% | 516.41 | 1277 / 1445 | 62% | 4.31 | 113 / 183 |
intestine | 84% | 418.01 | 810 / 966 | 46% | 2.17 | 243 / 527 |
skin | 99% | 3530.68 | 1796 / 1809 | 29% | 1.64 | 138 / 472 |
stomach | 74% | 256.86 | 266 / 359 | 50% | 3.17 | 142 / 286 |
adrenal gland | 98% | 780.73 | 254 / 258 | 24% | 1.36 | 56 / 230 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.00 | 1 / 1 |
adipose | 91% | 476.04 | 1100 / 1204 | 0% | 0 | 0 / 0 |
heart | 82% | 426.18 | 702 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 81% | 353.07 | 1086 / 1335 | 0% | 0 | 0 / 0 |
spleen | 77% | 283.88 | 186 / 241 | 0% | 0 | 0 / 0 |
brain | 11% | 40.82 | 291 / 2642 | 50% | 2.00 | 355 / 705 |
tonsil | 0% | 0 | 0 / 0 | 38% | 1.65 | 17 / 45 |
muscle | 2% | 8.36 | 16 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0046520 | Biological process | sphingoid biosynthetic process |
GO_0046512 | Biological process | sphingosine biosynthetic process |
GO_0046513 | Biological process | ceramide biosynthetic process |
GO_0017059 | Cellular component | serine palmitoyltransferase complex |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005515 | Molecular function | protein binding |
GO_0004758 | Molecular function | serine C-palmitoyltransferase activity |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
Gene name | SPTLC3 |
Protein name | Serine palmitoyltransferase long chain base subunit 3 (Serine palmitoyltransferase, long chain base subunit 2-like (Aminotransferase 2)) Serine palmitoyltransferase long chain base subunit 3 Serine palmitoyltransferase 3 (EC 2.3.1.50) (Long chain base biosynthesis protein 2b) (LCB2b) (Long chain base biosynthesis protein 3) (LCB 3) (Serine-palmitoyl-CoA transferase 3) (SPT 3) |
Synonyms | RP5-1077I2.1-002 C20orf38 SPTLC2L RP5-1077I2.1-001 |
Description | FUNCTION: Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases . The SPT complex is composed of SPTLC1, SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer consisting of SPTLC1 and SPTLC2/SPTLC3 forms the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference . The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA. The SPTLC1-SPTLC2-SPTSSB complex shows a strong preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SPTSSB isozyme displays an ability to use a broader range of acyl-CoAs, without apparent preference . . |
Accessions | Q9NUV7 ENST00000431275.1 ENST00000399002.7 [Q9NUV7-1] B1AKS3 ENST00000434210.5 B1AKS2 H0Y733 ENST00000450297.1 |